Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones involves significant challenges and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score simplifies the process of identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Progyny (PGNY) is currently highlighted as a recommended growth stock, featuring a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly desirable as it indicates strong future prospects [4] - Progyny has a historical EPS growth rate of 15.2%, but projected EPS growth for this year is expected to be 500%, significantly surpassing the industry average of 14.6% [5] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for assessing efficiency in growth investing [6] - Progyny's S/TA ratio stands at 1.75, indicating that the company generates $1.75 in sales for every dollar in assets, compared to the industry average of 0.76 [6] Group 4: Sales Growth - Sales growth is another key indicator, with Progyny expected to achieve a sales growth rate of 9.2% this year, while the industry average is projected at 0% [7] Group 5: Earnings Estimate Revisions - Trends in earnings estimate revisions are correlated with stock price movements, making them a valuable indicator for investors [8] - Progyny's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 8% over the past month [9] Group 6: Overall Positioning - Progyny has achieved a Zacks Rank of 2 due to positive earnings estimate revisions and has earned a Growth Score of A based on several favorable metrics [11] - This combination positions Progyny well for potential outperformance, making it an attractive option for growth investors [11]

Group 1: Stock Performance and Rankings - Pediatrix Medical Group, Inc. (MD) has a Zacks Rank 1 and its earnings estimate increased by 15.7% over the last 60 days [1] - Pediatrix's shares gained 35.4% over the last three months, significantly outperforming the S&P 500's 2.9% increase [2] - La-Z-Boy Incorporated (LZB) also holds a Zacks Rank 1 with a 3.2% increase in its earnings estimate over the last 60 days [2] - La-Z-Boy's shares increased by 3% over the last three months, matching the S&P 500's performance [2] - Grupo Cibest S.A. (CIB) has a Zacks Rank 1 and its earnings estimate rose by 8.7% over the last 60 days [3] - Grupo Cibest's shares increased by 22.1% over the last three months, again outperforming the S&P 500 [3] Group 2: Momentum Scores - Pediatrix Medical Group possesses a Momentum Score of A, indicating strong momentum characteristics [2] - La-Z-Boy has a Momentum Score of B, reflecting moderate momentum [2] - Grupo Cibest also holds a Momentum Score of B, suggesting a similar level of momentum as La-Z-Boy [3]

Core Insights - Wall Street experienced a rebound on November 21, 2025, with all three major stock indices rising nearly 1% due to investor optimism about a potential rate cut in December following dovish comments from John Williams, president of the Federal Reserve Bank of New York [1] Market Conditions - Despite the rebound, concerns over overvalued AI stocks persist, which could lead to a sell-off in the broader market at any time [2] Investment Strategy - In the current unstable environment, equity investors are advised to avoid high-priced stocks and consider dividend-growth stocks, as these companies typically exhibit strong financial health and provide a defensive hedge against economic uncertainty [3][5] - Dividend-growth stocks are characterized by a history of increasing dividends, which offers downside protection and potential for capital appreciation [5][6] Selected Dividend Growth Stocks - Five dividend growth stocks identified as solid choices include: - **Cardinal Health (CAH)**: Expected fiscal 2026 revenue growth of 16.2%, long-term earnings growth rate of 13.9%, and an annual dividend yield of 0.98% [12][13] - **Barrick Mining (B)**: Projected 2025 revenue growth of 21.5%, long-term earnings growth rate of 38.4%, and an annual dividend yield of 1.64% [14] - **NetEase (NTES)**: Anticipated 2025 revenue growth of 10.4%, long-term earnings growth rate of 9.9%, and an annual dividend yield of 1.70% [15] - **Lam Research (LRCX)**: Expected fiscal 2026 revenue growth of 14.1%, long-term earnings growth rate of 20.3%, and an annual dividend yield of 0.73% [16] - **Enersys (ENS)**: Projected fiscal 2026 revenue growth of 4%, long-term earnings growth rate of 15%, and an annual dividend yield of 0.76% [17] Selection Criteria - The selection of these stocks is based on criteria such as multi-year growth in dividends, sales, earnings per share (EPS), and undervaluation metrics [10][11] - Stocks selected have shown historical growth in dividends, sales, and EPS, indicating strong fundamentals and potential for sustained dividend payments [8][9]

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Molina Healthcare, Inc. (NYSE: MOH). Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/ ...

Group 1 - Amer Sports, Inc. has seen a Zacks Consensus Estimate increase of 8.3% for its current year earnings over the last 60 days [1] - Intuitive Surgical, Inc. has experienced a 5.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Pediatrix Medical Group, Inc. has had a significant increase of 15.7% in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Seanergy Maritime Holdings Corp. has seen a remarkable 66.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Grupo Cibest S.A. has experienced an 8.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price, which fell over 33% after the company reported disappointing Q3 2025 financial results [1][3][4]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue due to "hindsight evaluations of historical collection trends" [4]. - The company also increased its professional liability reserves by $54 million, citing "adverse prior period claim developments" from claims between 2019 and 2022, as well as broader industry trends [4]. Investigation Details - The investigation focuses on Ardent's accounting practices, particularly regarding accounts receivable and professional liability reserves [3]. - Bleichmar Fonti & Auld LLP, a leading securities law firm, is conducting the investigation and has urged investors to come forward [1][5].

Core Insights - Three stocks are highlighted with a buy rank and strong value characteristics for investors to consider on November 24 Group 1: John B. Sanfilippo & Son, Inc. (JBSS) - The company operates in the tree nuts and peanuts sector and holds a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 7.8% over the last 60 days [1] - The price-to-earnings ratio (P/E) is 11.84, significantly lower than the industry average of 29.50 [1] - The company has a Value Score of A [1] Group 2: Grupo Cibest S.A. (CIB) - This company provides banking services and products and also holds a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 8.7% over the last 60 days [2] - The price-to-earnings ratio (P/E) is 7.81, compared to 24.24 for the S&P 500 [2] - The company has a Value Score of B [2] Group 3: Pediatrix Medical Group, Inc. (MD) - The company specializes in newborn care, maternal-fetal medicine, and pediatric subspecialty services, holding a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 15.7% over the last 60 days [3] - The price-to-earnings ratio (P/E) is 11.19, lower than the S&P 500 average of 24.24 [3] - The company has a Value Score of B [3]

Group 1 - InterGlobe Aviation will be added to the BSE Sensex index, replacing Tata Motors Passenger Vehicles, effective from December 22 [4][3] - The inclusion of InterGlobe Aviation indicates its growing market presence and reflects a significant shift in sector representation within the benchmark, moving from automobiles to aviation [4][3] - The reshuffle will also involve changes in other indices, with IDFC First Bank replacing Adani Green Energy in the BSE 100 index and Max Healthcare Institute replacing IndusInd Bank in the BSE Sensex 50 [4][3] Group 2 - Index changes typically lead to portfolio realignment among index-tracking funds and exchange-traded funds, resulting in mechanical buying and selling as funds adjust their holdings [3][4] - The announcement of these changes highlights the evolving dynamics within India's equity markets and the shifts in category leadership over time [4]

Group 1 - UnitedHealth Group Incorporated (NYSE:UNH) is receiving positive attention from analysts, with a consensus 1-year median price target of $410, indicating a potential upside of 28% [1] - Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400, while a Barclays analyst maintained a Buy rating with a price target of $386 [1] - The company announced the addition of Scott Gottlieb, former FDA commissioner, to its board, effective immediately [2] Group 2 - Scott Gottlieb is recognized for his public health advocacy, particularly in reducing flavored e-cigarette use among youths, and has experience in enhancing competition through expedited approvals [3] - UnitedHealth operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, and is committed to improving the healthcare system since its founding in 1974 [4]

Core Viewpoint - The upcoming reshuffle in the BSE Sensex on December 22 signifies a shift in India's equity benchmark, with InterGlobe Aviation replacing Tata Motors Passenger Vehicles, reflecting changes in market leadership and corporate restructuring [5]. Group 1: Index Changes - InterGlobe Aviation will replace Tata Motors Passenger Vehicles in the Sensex index, marking a significant transition in the index composition [5]. - IDFC First Bank Ltd will be included in the BSE 100 index, replacing Adani Green Energy Ltd [5]. - Max Healthcare Institute Ltd will be added to the BSE Sensex 50, while IndusInd Bank Ltd will be removed [5]. - In the BSE Sensex Next 50 index, IndusInd Bank and IDFC First Bank will replace Max Healthcare Institute Ltd and Adani Green Energy [5]. Group 2: Market Implications - The inclusion of InterGlobe Aviation indicates its growing market prominence, while Tata Motors PV's exit is attributed to its recent demerger from Tata Motors [5]. - The rebalancing of the indices ensures they remain representative of India's evolving market landscape [4][5]. - The changes will necessitate mandatory reallocation by index-tracking funds and exchange-traded funds, leading to mechanical buying and selling as portfolios adjust to the new index composition [4][5].